21.67

3.52% -0.79

Pre-market: 21.36 -0.31 -1.43%

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $21.67, with a volume of 1.14M. It is down -3.52% in the last 24 hours and down -0.87% over the past month. Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Previous Close:

$22.46

Open:

$22.56

24h Volume:

1.14M

Relative Volume:

0.74

Market Cap:

$2.45B

Revenue:

$6.94M

Net Income/Loss:

$-212.39M

P/E Ratio:

-8.925

EPS:

-2.428

Net Cash Flow:

$-200.60M

1W Performance:

-0.78%

1M Performance:

-0.87%

6M Performance:

+55.68%

1Y Performance:

+249.52%

1-Day Range:

$21.54

$22.61

1-Week Range:

$20.78

$22.70

52-Week Range:

$6.09

$27.65

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1105)

Industry

Biotechnology (623)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

177

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	21.67	2.45B	6.94M	-212.39M	-200.60M	-2.428
VRTX Vertex Pharmaceuticals Inc	436.27	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	748.87	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	799.65	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	322.11	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	309.66	34.37B	5.36B	287.73M	924.18M	2.5229

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Initiated	H.C. Wainwright	Buy
Dec-01-25	Initiated	Truist	Buy
Sep-22-25	Initiated	Goldman	Buy
Sep-05-25	Initiated	Craig Hallum	Buy
Apr-02-25	Initiated	Lake Street	Buy
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

Apr 10, 2026

Avoiding Lag: Real-Time Signals in (IMNM) Movement - Stock Traders Daily

Apr 10, 2026

IMNM News | IMMUNOME INC (NASDAQ:IMNM) - ChartMill

Apr 10, 2026

Apr 08, 2026

Death Cross: Is Immunome Inc gaining market share2026 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Apr 07, 2026

Apr 05, 2026

Immunome CSO Sells Shares: Transaction Details & Company SnapshotNews and Statistics - IndexBox

Apr 05, 2026

Immunome (IMNM) Is Up 11.4% After CEO Share Buy And Positive Phase III DataWhat's Changed - Sahm

Apr 05, 2026

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - AOL.com

Apr 05, 2026

Insider Sell: What is the long term forecast for Immunome Inc stockDividend Hike & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - The Motley Fool

Apr 04, 2026

A Look At Immunome (IMNM) Valuation After Oncology Progress EPS Upgrades And CEO Insider Buying - Sahm

Apr 04, 2026